論文 - 詳細
| RRC ID | 37622 |
|---|---|
| 著者 | Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. |
| タイトル | MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. |
| ジャーナル | Blood |
| Abstract |
Aberrant overexpression of the miR-17-92 polycistron is strongly associated with B-cell lymphomagenesis. Recent studies have shown that miR-17-92 down-regulates the proapoptotic protein Bim, leading to overexpression of Bcl2, which likely plays a key role in lymphomagenesis. However, the fact that Jeko-1 cells derived from mantle cell lymphoma exhibit both homozygous deletion of BIM and overexpression of miR-17-92 suggests other targets are also involved in B-cell lymphomagenesis. To identify essential target(s) of miR-17-92 in lymphomagenesis, we first transfected miR-17-92 into 2 genetically distinct B-cell lymphoma cell lines: Raji, which overexpress c-Myc, and SUDHL4, which overexpress Bcl2. Raji transfected with miR-17-19b-1 exhibited down-regulated expression of Bim and a slight up-regulation in Bcl2 expression. On the other hand, SUDHL4 transfectants showed aggressive cell growth reflecting facilitated cell cycle progression at the G(1) to S transition and decreased expression of CDKN1A mRNA and p21 protein (CDKN1A/p21) that was independent of p53 expression. Conversely, transfection of antisense oligonucleotides against miR-17 and miR-20a into Jeko-1 led to up-regulation of CDKN1A/p21, resulting in decreased cell growth with G(1) to S arrest. Thus, CDKN1A/p21 appears to be an essential target of miR-17-92 during B-cell lymphomagenesis, which suggests the miR-17-92 polycistron has distinct targets in different B-cell lymphoma subtypes. |
| 巻・号 | 113(2) |
| ページ | 396-402 |
| 公開日 | 2009-1-8 |
| DOI | 10.1182/blood-2008-07-163907 |
| PII | S0006-4971(20)37888-5 |
| PMID | 18941111 |
| MeSH | Animals Apoptosis / drug effects Apoptosis / genetics Cell Line, Tumor G1 Phase / drug effects G1 Phase / genetics Gene Expression Regulation, Leukemic* / drug effects Humans Lymphoma, B-Cell / genetics Lymphoma, B-Cell / metabolism* MicroRNAs / antagonists & inhibitors MicroRNAs / genetics MicroRNAs / metabolism* Neoplasm Proteins / biosynthesis* Neoplasm Proteins / genetics Oligodeoxyribonucleotides, Antisense / genetics Oligodeoxyribonucleotides, Antisense / pharmacology RNA, Neoplasm / antagonists & inhibitors RNA, Neoplasm / genetics RNA, Neoplasm / metabolism* Rats S Phase / drug effects S Phase / genetics |
| IF | 17.794 |
| 引用数 | 192 |
| WOS 分野 | HEMATOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 5 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | Rat-1(RCB1830) |